Clinic-based Procedures for Headache.
Journal
Continuum (Minneapolis, Minn.)
ISSN: 1538-6899
Titre abrégé: Continuum (Minneap Minn)
Pays: United States
ID NLM: 9509333
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
26
11
2021
Statut:
ppublish
Résumé
Headache disorders are common and disabling, and many therapies that are effective and safe are procedural. After pivotal clinical trials, onabotulinumtoxinA has become an established preventive therapy for chronic migraine; it is better tolerated than many other treatments and may be useful for other headache disorders. Peripheral nerve blocks, especially greater occipital nerve blocks, have amassed evidence from randomized trials in the acute and short-term preventive treatment of migraine and cluster headache. Trigger point injections and sphenopalatine ganglion blocks have recent trials suggesting efficacy and safety in properly selected patients. Medical education initiatives are needed to train neurologists in these procedures to help manage the large population of patients with headache disorders who need them. Evidence exists for the efficacy and safety of procedural therapies to be incorporated into neurology practice for the management of patients with migraine, cluster headache, and other headache disorders.
Identifiants
pubmed: 34048401
doi: 10.1212/CON.0000000000000959
pii: 00132979-202106000-00013
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
732-745Informations de copyright
Copyright © 2021 American Academy of Neurology.
Références
Adornato BT, Drogan O, Thoresen P, et al. The practice of neurology, 2000-2010: report of the AAN Member Research Subcommittee. Neurology 2011;77(21):1921–1928. doi:10.1212/WNL.0b013e318238ee13
doi: 10.1212/WNL.0b013e318238ee13
Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793–803. doi:10.1177/0333102410364676
doi: 10.1177/0333102410364676
Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30(7):804–814. doi:10.1177/0333102410364677
doi: 10.1177/0333102410364677
Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. Pain 2005;118(1-2):92–96. doi:10.1016/j.pain.2005.07.015
doi: 10.1016/j.pain.2005.07.015
Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10(10):891–897. doi:10.1016/S1474-4422(11)70186-7
doi: 10.1016/S1474-4422(11)70186-7
Inan LE, Inan N, Karadas Ö, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. Acta Neurol Scand 2015;132(4):270–277. doi:10.1111/ane.12393
doi: 10.1111/ane.12393
Palamar D, Uluduz D, Saip S, et al. Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura?Pain Physician 2015;18(2):153–162.
Cuadrado ML, Aledo-Serrano Á, Navarro P, et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia 2017;37(9):864–872.
Gul HL, Ozon AO, Karadas O, et al. The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. Acta Neurol Scand 2017;136(2):138–144. doi:10.1111/ane.12716
doi: 10.1111/ane.12716
Karadaş Ö, Gül HL, Inan LE. Lidocaine injection of pericranial myofascial trigger points in the treatment of frequent episodic tension-type headache. J Headache Pain 2013;14(1):44. doi:10.1186/1129-2377-14-44
doi: 10.1186/1129-2377-14-44
Karadaş Ö, Inan LE, Ümit UH, Odabaşi Z. Efficacy of local lidocaine application on anxiety and depression and its curative effect on patients with chronic tension-type headache. Eur Neurol 2013;70(1-2):95–101. doi:10.1159/000350619
doi: 10.1159/000350619
Ondo WG, Simmons JH, Shahid MH, et al. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study. Neurology 2018;90(7):e559–e564. doi:10.1212/WNL.0000000000004951
doi: 10.1212/WNL.0000000000004951
Ali A, Kriegler J, Tepper S, Vij B. New daily persistent headache and OnabotulinumtoxinA therapy. Clin Neuropharmacol 2019;42(1):1–3. doi:10.1097/WNF.0000000000000313
doi: 10.1097/WNF.0000000000000313
Yerry JA, Kuehn D, Finkel AG. Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache 2015;55(3):395–406. doi:10.1111/head.12495
doi: 10.1111/head.12495
García-Azorín D, Trigo-López J, Sierra Á, et al. Observational, open-label, non-randomized study on the efficacy of onabotulinumtoxinA in the treatment of nummular headache: the pre-numabot study. Cephalalgia 2019;39(14):1818–1826. doi:10.1177/0333102419863023
doi: 10.1177/0333102419863023
Wei J, Zhu X, Yang G, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: a meta-analysis of randomized controlled trials. Brain Behav 2019;9(10):e01409. doi:10.1002/brb3.1409
doi: 10.1002/brb3.1409
Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. Cephalalgia 2015;35(11):959–968. doi:10.1177/0333102414561872
doi: 10.1177/0333102414561872
Friedman BW, Mohamed S, Robbins MS, et al. A randomized, sham-controlled trial of bilateral greater occipital nerve blocks with bupivacaine for acute migraine patients refractory to standard emergency department treatment with metoclopramide. Headache 2018;58(9):1427–1434. doi:10.1111/head.13395
doi: 10.1111/head.13395
Korucu O, Dagar S, Corbacioglu SK, et al. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta Neurol Scand 2018;138(3):212–218. doi:10.1111/ane.12952
doi: 10.1111/ane.12952
Gelfand AA, Reider AC, Goadsby PJ. Outcomes of greater occipital nerve injections in pediatric patients with chronic primary headache disorders. Pediatr Neurol 2014;50(2):135–139. doi:10.1016/j.pediatrneurol.2013.09.008
doi: 10.1016/j.pediatrneurol.2013.09.008
Govindappagari S, Grossman TB, Dayal AK, et al. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstet Gynecol 2014;124(6):1169–1174. doi:10.1097/AOG.0000000000000555
doi: 10.1097/AOG.0000000000000555
Hascalovici JR, Robbins MS. Peripheral nerve blocks for the treatment of headache in older adults: a retrospective study. Headache 2017;57(1):80–86. doi:10.1111/head.12992
doi: 10.1111/head.12992
Cady R, Saper J, Dexter K, Manley HR. A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360(®) as acute treatment for chronic migraine. Headache 2015;55(1):101–116. doi:10.1111/head.12458
doi: 10.1111/head.12458
Cady RK, Saper J, Dexter K, et al. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. Headache 2015;55(4):529–542. doi:10.1111/head.12546
doi: 10.1111/head.12546
Schaffer JT, Hunter BR, Ball KM, Weaver CS. Noninvasive sphenopalatine ganglion block for acute headache in the emergency department: a randomized placebo-controlled trial. Ann Emerg Med 2015;65(5):503–510. doi:10.1016/j.annemergmed.2014.12.012
doi: 10.1016/j.annemergmed.2014.12.012
Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921–936. doi:10.1111/j.1526-4610.2010.01678.x
doi: 10.1111/j.1526-4610.2010.01678.x
Solomon S. Botulinum toxin for the treatment of chronic migraine: the placebo effect. Headache 2011;51(6):980–984. doi:10.1111/j.1526-4610.2011.01915.x
doi: 10.1111/j.1526-4610.2011.01915.x
Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13. doi:10.1186/s10194-018-0840-8
doi: 10.1186/s10194-018-0840-8
Dodick DW, Silberstein SD, Lipton RB, et al. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data. Cephalalgia 2019;39(8):945–956. doi:10.1177/0333102418825382
doi: 10.1177/0333102418825382
Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(suppl 1):S9–S15. doi:10.1046/j.1526-4610.43.7s.3.x
doi: 10.1046/j.1526-4610.43.7s.3.x
Zhang X, Strassman AM, Novack V, et al. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?Cephalalgia 2016;36(9):875–886. doi:10.1177/0333102416636843
doi: 10.1177/0333102416636843
Kosaras B, Jakubowski M, Kainz V, Burstein R. Sensory innervation of the calvarial bones of the mouse. J Comp Neurol 2009;515(3):331–348. doi:10.1002/cne.22049
doi: 10.1002/cne.22049
Blumenfeld AM, Silberstein SD, Dodick DW, et al. Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes. Headache 2017;57(5):766–777. doi:10.1111/head.13074
doi: 10.1111/head.13074
Rothrock JF, Adams AM, Lipton RB, et al. FORWARD study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 2019;59(10):1700–1713. doi:10.1111/head.13653
doi: 10.1111/head.13653
Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis?J Forensic Sci 2005;50(1):169–172. doi:10.1520/JFS2004196
doi: 10.1520/JFS2004196
Morgan JC, Iyer SS, Moser ET, et al. Botulinum toxin A during pregnancy: a survey of treating physicians. J Neurol Neurosurg Psychiatry 2006;77(1):117–119. doi:10.1136/jnnp.2005.063792
doi: 10.1136/jnnp.2005.063792
Ahmed F, Khali M, Tanvir T, Buture A. OnabotulinumtoxinA for chronic migraine during pregnancy; experience from Hull Migraine Clinic, United Kingdom. Cephalalgia 2018;38(suppl 1):87. 17th Biennial Migraine Trust International Symposium abstract MTIS2018-104.
Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf 2016;25(2):179–187. doi:10.1002/pds.3920
doi: 10.1002/pds.3920
Masters-Israilov A, Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache 2019;59(10):1753–1761. doi:10.1111/head.13638
doi: 10.1111/head.13638
Zidan A, Roe C, Burke D, Mejico L. OnabotulinumtoxinA wear-off in chronic migraine, observational cohort study. J Clin Neurosci 2019;69:237–240. doi:10.1016/j.jocn.2019.07.043
doi: 10.1016/j.jocn.2019.07.043
Blumenfeld A, Ashkenazi A, Napchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches—a narrative review. Headache 2013;53(3):437–446. doi:10.1111/head.12053
doi: 10.1111/head.12053
Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes—prolonged effects from a single injection. Pain 2006;122(1-2):126–129. doi:10.1016/j.pain.2006.01.016
doi: 10.1016/j.pain.2006.01.016
Ailani J, Robbins MS, Blumenfeld A. Peripheral nerve blocks for headache in clinical practice: a multicenter, prospective registry study. Headache 2014;54(S1):9. American Headache Society abstract OR16.
Robbins MS. Peripheral nerve blocks, steroid injections and their niche in headache medicine. Cephalalgia 2015;35(10):850–852. doi:10.1177/0333102414561874
doi: 10.1177/0333102414561874
Friedman BW, Irizarry E, Williams A, et al. A randomized, double-dummy, emergency department-based study of greater occipital nerve bock with bupivacaine vs intravenous metoclopramide for treatment of migraine. Headache 2020;60(10):2380–2388. doi:10.1111/head.13961
doi: 10.1111/head.13961
Kiarashi J, Jion Y, Giglio B, et al. Elective hospitalizations for intractable headache: outcomes and response predictors. Neurol Clin Pract 2020:10.1212/CPJ.0000000000000965. doi:10.1212/CPJ.0000000000000965
doi: 10.1212/CPJ.0000000000000965. doi:10.1212/CPJ.0000000000000965
Wei J, Robbins MS. Greater occipital nerve injection versus oral steroids for short term prophylaxis of cluster headache: a retrospective comparative study. Headache 2018;58(6):852–858. doi:10.1111/head.13334
doi: 10.1111/head.13334
Robbins MS, Starling AJ, Pringsheim TM, et al. Treatment of cluster headache: the American Headache Society Evidence-Based Guidelines. Headache 2016;56(7):1093–1106. doi:10.1111/head.12866
doi: 10.1111/head.12866
Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia 2019;39(12):1488–1499. doi:10.1177/0333102419848121
doi: 10.1177/0333102419848121
Smith JH, Potter JL, Robblee JV. What is the optimal placebo for clinical trials of nerve blocks in headache?: an n-of-1 study of lactated Ringer's. Headache 2019;59(1):108–109. doi:10.1111/head.13441
doi: 10.1111/head.13441
Ashkenazi A, Matro R, Shaw JW, et al. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. J Neurol Neurosurg Psychiatry 2008;79(4):415–417. doi:10.1136/jnnp.2007.124420
doi: 10.1136/jnnp.2007.124420
Kashipazha D, Nakhostin-Mortazavi A, Mohammadianinejad SE, et al. Preventive effect of greater occipital nerve block on severity and frequency of migraine headache. Glob J Health Sci 2014;6(6):209–213. doi:10.5539/gjhs.v6n6p209
doi: 10.5539/gjhs.v6n6p209
Narouze S. Occipital neuralgia diagnosis and treatment: the role of ultrasound. Headache 2016;56(4):801–807.
Moller RA, Covino BG. Effect of progesterone on the cardiac electrophysiologic alterations produced by ropivacaine and bupivacaine. Anesthesiology 1992;77(4):735–741. doi:10.1097/00000542-199210000-00018
doi: 10.1097/00000542-199210000-00018
Santos AC, Pedersen H, Harmon TW, et al. Does pregnancy alter the systemic toxicity of local anesthetics?Anesthesiology 1989;70(6):991–995. doi:10.1097/00000542-198906000-00018
doi: 10.1097/00000542-198906000-00018
Robbins MS, Kuruvilla D, Blumenfeld A, et al. Trigger point injections for headache disorders: expert consensus methodology and narrative review. Headache 2014;54(9):1441–1459. doi:10.1111/head.12442
doi: 10.1111/head.12442
Weller JL, Comeau D, Otis JAD. Myofascial pain. Semin Neurol 2018;38(6):640–643. doi:10.1055/s-0038-1673674
doi: 10.1055/s-0038-1673674
Robbins MS, Robertson CE, Kaplan E, et al. The sphenopalatine ganglion: anatomy, pathophysiology, and therapeutic targeting in headache. Headache 2016;56(2):240–258. doi:10.1111/head.12729
doi: 10.1111/head.12729
Burkett JG, Robbins MS, Robertson CE, et al. Sphenopalatine ganglion block in primary headaches: an American Headache Society member survey. Neurol Clin Pract 2020:10(6):503–509. doi:10.1212/CPJ.0000000000000773
doi: 10.1212/CPJ.0000000000000773
Crespi J, Bratbak D, Dodick D, et al. Measurement and implications of the distance between the sphenopalatine ganglion and nasal mucosa: a neuroimaging study. J Headache Pain 2018;19(1):14. doi:10.1186/s10194-018-0843-5
doi: 10.1186/s10194-018-0843-5
Bratbak DF, Nordgard S, Stovner LJ, et al. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic cluster headache. Cephalalgia 2016;36(6):503–509. doi:10.1177/0333102415597891
doi: 10.1177/0333102415597891
Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343–349. doi:10.1212/01.wnl.0000252808.97649.21
doi: 10.1212/01.wnl.0000252808.97649.21
Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(10):1456–1470. doi:10.1111/j.1526-4610.2012.02223.x
doi: 10.1111/j.1526-4610.2012.02223.x
Kommineni M, Finkel AG. Teaching headache in America: survey of neurology chairs and residency directors. Headache 2005;45(7):862–865. doi:10.1111/j.1526-4610.2005.05154.x
doi: 10.1111/j.1526-4610.2005.05154.x
Robbins MS, Robertson CE, Ailani J, et al. Procedural headache medicine in neurology residency training: a survey of US program directors. Headache 2016;56(1):79–85. doi:10.1111/head.12695
doi: 10.1111/head.12695
Levin M. Milestones in fellowship training in headache medicine. Headache 2016;56(1):185–188. doi:10.1111/head.12743
doi: 10.1111/head.12743
Mauser ED, Rosen NL. So many migraines, so few subspecialists: analysis of the geographic location of United Council for Neurologic Subspecialties (UCNS) certified headache subspecialists compared to United States headache demographics. Headache 2014;54(8):1347–1357. doi:10.1111/head.12406
doi: 10.1111/head.12406